Additionally, immune checkpoint inhibitors (e.g., programmed cell death protein 1 [PD-1]/programmed death-ligand 1 [PD-L1] inhibitors) have become a focus, harnessing the patient’s immune system to fight the tumor. Here, PDCD1 is linked to neoplasm.